Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-Thalidomide versus MP-Lenalidomide with maintenance in elderly untreated multiple myeloma
NL-OMON50624Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan, prednisone, thalidomide and lenalidomide in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoints: Progression-free survival and Deep response rate. Started Mar 2009; status: active, not recruiting.
02
Drugs
melphalanprednisonethalidomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON50624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50624.